- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03878589
Understanding Cognition, Oxytocin & Pain in Elders (UCOPE)
Mechanisms Underlying Oxytocin's Analgesia in Older Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Osteoarthritis (OA) represents a significant cause of disability worldwide in individuals aged 65 and older, a rapidly growing segment of our population. The knee is the most commonly affected joint with pain being the primary symptom, negatively impacting physical, cognitive, and emotional functioning. Symptomatic knee OA has been traditionally attributed to peripheral mechanisms, but measures of joint damage only modestly account for the presence or severity of OA-related pain. The neuropeptide oxytocin (OT) has been recognized as a mediator of endogenous analgesia in animal and human studies. However, little is known about the neurobiological mechanisms underlying OT's pain-relieving properties.
This study will test the efficacy and safety of self-administered intranasal OT over 4-weeks in older individuals with knee osteoarthritis. Relative to placebo (P), daily administration of intranasal OT diminished self-reported pain, physical and emotional functioning and changes in brain metabolite concentrations. With strong support from the University of Florida and the McKnight Brain Institute, this interdisciplinary project, using a comprehensive multi-methods approach, will be the first to determine the potential benefit of OT as a novel analgesic therapy for knee OA pain in aging.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Yenisel Cruz-Almeida, PhD, MSPH
- Phone Number: 352-294-5845
- Email: cryeni@ufl.edu
Study Contact Backup
- Name: Natalie Ebner, PhD
- Email: natalie.ebner@ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- UF Health of University of Florida
-
Gainesville, Florida, United States, 32603
- Recruiting
- Department of Community Dentistry and Behavioral Science
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- knee osteoarthritis/or back pain of at least six months duration, experience pain on more days than not, with moderate pain at baseline (i.e., > 3/6 in the VDS), and who have elevated levels of plasma IL-6 (>2.5 pg/ml) will be considered for participation.
Exclusion Criteria:
- Hypersensitivity to OT or vasopressin,
- history of hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, or psychogenic polydipsia,
- on vasoconstrictors such as desmopressin, pseudoephedrine, or antidiuretic medication,
- low sodium and high osmolality levels,
- excessive smoking,
- excessive drinking,
- muscle pain as a result of systemic disease,
- significant nasal pathology,
- previous or concurrent use of narcotics delivered intranasally (e.g., cocaine),
- gastroparesis.
- individuals with heart problems (e.g., cardiomyopathy, history of myocardial infarction, arrhythmias, prolonged QT interval)
- Participants will also be excluded if they have concurrent medical or arthritic conditions that could confound symptomatic knee OA-related outcomes or coexisting disease that could preclude successful completion of the protocol including:
- systemic rheumatic condition (e.g. rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia);
- a history of clinically significant surgery to the index knee;
- uncontrolled hypertension (>150/95);
- poorly controlled diabetes (HbA1c>7%);
- neurological disease (e.g., Parkinson's, Multiple Sclerosis);
- cardiovascular or peripheral arterial disease;
- serious psychiatric disorder requiring hospitalization within the past twelve months or characterized by active suicidal ideation;
- diminished cognitive function that would interfere with completion of study procedures (i.e., MoCA score < 25)]; and
- large pieces of metal in the body or metal in the face or neck,
- claustrophobia,
- major medical surgery in the past two months,
- history of brain surgery or any serious brain condition like aneurysm, stroke, or seizures].
- pregnant individuals will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Oxytocin Crossover Placebo Group
During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of oxytocin (OT) twice a day at home, at 8-9AM and again at 5-6PM.
After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of placebo (P) twice a day will be self-administered.
|
During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data.
During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data.
During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
|
Active Comparator: Placebo Crossover Oxytocin Group
During Phase 1 of the intervention, participants will self-administer via intranasal spray 24 IUs of placebo (P) twice a day at home, at 8-9AM and again at 5-6PM.
After a four-week washout period, Phase 2 will consist of a second four weeks of intervention, this time intranasal spray 24 IUs of oxytocin (OT) twice a day will be self-administered.
|
During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data.
During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data.
During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in WOMAC (Western Ontario and McMaster Universities Osteoarthritis) Index
Time Frame: Baseline; Week 1; Week 2; Week 3; Week 4; Week 9; Week 10; Week 11; Week 12
|
Self-reported pain and function.
Summary scores of the WOMAC range from 0 (No pain or disability) to 96 (Extreme pain or disability).
|
Baseline; Week 1; Week 2; Week 3; Week 4; Week 9; Week 10; Week 11; Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Frontal Cortex Brain Metabolites
Time Frame: Baseline; Week 1; Week 2; Week 3; Week 4; Week 9; Week 10; Week 11; Week 12
|
Track levels of the frontal cortex brain chemicals (tCr, MI, Cho) through use of magnetic resonance spectroscopy (MRS).
|
Baseline; Week 1; Week 2; Week 3; Week 4; Week 9; Week 10; Week 11; Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yenisel Cruz-Almeida, PhD, MSPH, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201801467-N
- R01AG059809 (U.S. NIH Grant/Contract)
- OCR18586 (Other Identifier: UF OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Oxytocin (OT)
-
University Hospital, ToulouseEpidemiological and Clinical Research Information Network; International Clinical...CompletedPrader-Willi SyndromeFrance, Belgium, Germany
-
Rodrigo CardenasU.S. National Science FoundationCompleted
-
Icahn School of Medicine at Mount SinaiRecruitingBorderline Personality DisorderUnited States
-
Azienda Ospedaliero-Universitaria di ParmaUniversity of ParmaWithdrawnCovid-19 | SARS-CoV 2 | Corona Virus InfectionItaly, France
-
Linmarie SikichEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedAutism Spectrum DisordersUnited States
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Active, not recruiting
-
The University of Texas Medical Branch, GalvestonUniversity of Texas Southwestern Medical Center; United States Army Institute... and other collaboratorsCompletedMuscle Weakness | Muscle; Fatigue, Heart | Late Effect of Burn | Burn RehabilitationUnited States
-
Seoul National University Bundang HospitalActive, not recruitingStroke | HemiplegiaKorea, Republic of
-
Oncotartis, Inc.UnknownLymphoma | Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, T-Cell | Lymphoma, Hodgkin | Lymphoma, Peripheral T-CellUnited States
-
Henry Ford Health SystemHenry Ford HospitalCompletedTranscatheter Aortic Valve ImplantationUnited States